Each scoop delivers one gram of granules which contains 33 mg of tenofovir disoproxil (as fumarate).
Excipient with known effect: One gram of granules contains 622 mg mannitol.
For the full list of excipients, see section 6.1.
Granules.
White, taste masked, coated granules.
HIV-1 infection
Viread 33 mg/g granules are indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, from 2 to < 6 years of age, and above 6 years of age for whom a solid dosage form is not appropriate.
Viread 33 mg/g granules are also indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults for whom a solid dosage form is not appropriate.
In adults, the demonstration of the benefit of Viread in HIV-1 infection is based on results of one study in treatment-naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which Viread was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml).
The choice of Viread to treat antiretroviral-experienced patients with HIV-1 infection should be based on individual viral resistance testing and/or treatment history of patients.
Hepatitis B infection
Viread 33 mg/g granules are indicated for the treatment of chronic hepatitis B in adults for whom a solid dosage form is not appropriate with:
• compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis (see section 5.1).
• evidence of lamivudine-resistant hepatitis B virus (see sections 4.8 and 5.1).
• decompensated liver disease (see sections 4.4, 4.8 and 5.1).
Viread 33 mg/g granules are also indicated for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age for whom a solid dosage form is not appropriate with:
• compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis (see sections 4.4, 4.8 and 5.1).
Therapy should be initiated by a physician experienced in the management of HIV infection and/or treatment of chronic hepatitis B.
Posology
HIV-1: The recommended dose is 6.5 mg of tenofovir disoproxil (as fumarate) per kilogram of body weight once daily taken with food. Refer to Table 1.
Limited clinical data are available at the 6.5 mg/kg dose of the granules. Therefore, close monitoring of efficacy and safety is needed.
Table 1: Dosing for paediatric patients aged 2 to < 12 years
Body weight (kg)
|
Once daily
Scoops of granules
|
Total dose (mg) tenofovir disoproxil (as fumarate)
|
10 to < 12
|
2
|
65
|
12 to < 14
|
|
以下是“全球医药”详细资料 |
|
|